Abstract

BackgroundAt the DKMS Life Science Lab, Next Generation Sequencing (NGS) has been used for ultra-high-volume high-resolution genotyping of HLA loci for the last three and a half years. Here, we report on our experiences in genotyping the HLA, CCR5, ABO, RHD and KIR genes using a direct amplicon sequencing approach on Illumina MiSeq and HiSeq 2500 instruments.ResultsBetween January 2013 and June 2016, 2,714,110 samples largely from German, Polish and UK-based potential stem cell donors have been processed. 98.9% of all alleles for the targeted HLA loci (HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1) were typed at high resolution or better. Initially a simple three-step workflow based on nanofluidic chips in conjunction with 4-primer amplicon tagging was used. Over time, we found that this setup results in PCR artefacts such as primer dimers and PCR-mediated recombination, which may necessitate repeat typing. Split workflows for low- and high-DNA-concentration samples helped alleviate these problems and reduced average per-locus repeat rates from 3.1 to 1.3%. Further optimisations of the workflow included the use of phosphorothioate oligos to reduce primer degradation and primer dimer formation, and employing statistical models to predict read yield from initial template DNA concentration to avoid intermediate quantification of PCR products. Finally, despite the populations typed at DKMS Life Science Lab being relatively homogenous genetically, an analysis of 1.4 million donors processed between January 2015 and May 2016 led to the discovery of 1,919 distinct novel HLA alleles.ConclusionsAmplicon-based NGS HLA genotyping workflows have become the workhorse in high-volume tissue typing of registry donors. The optimisation of workflow practices over multiple years has led to insights and solutions that improve the efficiency and robustness of short amplicon based genotyping workflows.

Highlights

  • At the DKMS Life Science Lab, Generation Sequencing (NGS) has been used for ultra-highvolume high-resolution genotyping of human leukocyte antigen (HLA) loci for the last three and a half years

  • Until recently, unrelated stem-cell donor registries all over the world, which provide the bulk of this information, have utilised different serological and DNA-based HLA typing methods with variable resolution, such as sequence-specific oligonucleotide probes (SSOP), sequence-specific primer (SSP) PCR, or sequence-based typing (SBT) using Sanger sequencing

  • Based on data from the HLA core exons 2 and 3, between 96.78% (HLA-C) and 99.97% (HLA-DPB1) of the samples could be typed at high resolution or better as defined by EFI standard v6.3, with the exception that null alleles caused by a mutation outside of exons 2 and 3 remain unidentified (Table 1)

Read more

Summary

Introduction

At the DKMS Life Science Lab, Generation Sequencing (NGS) has been used for ultra-highvolume high-resolution genotyping of HLA loci for the last three and a half years. HLA genes encoding the 6 major antigen-presenting proteins (HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1) play a crucial role in solid organ and haematopoietic stem-cell. Full list of author information is available at the end of the article transplantation (HSCT), where outcome is mostly determined by the genetic concordance of HLA alleles between donors and recipients [2]. Until recently, unrelated stem-cell donor registries all over the world, which provide the bulk of this information, have utilised different serological and DNA-based HLA typing methods with variable resolution, such as sequence-specific oligonucleotide probes (SSOP), sequence-specific primer (SSP) PCR, or sequence-based typing (SBT) using Sanger sequencing

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.